263 related articles for article (PubMed ID: 23337264)
1. Therapeutic potential of tumour necrosis factor-alpha antagonists in patients with chronic heart failure.
Javed Q; Murtaza I
Heart Lung Circ; 2013 May; 22(5):323-7. PubMed ID: 23337264
[TBL] [Abstract][Full Text] [Related]
2. TNF-alpha, rheumatoid arthritis, and heart failure: a rheumatological dilemma.
Sarzi-Puttini P; Atzeni F; Shoenfeld Y; Ferraccioli G
Autoimmun Rev; 2005 Mar; 4(3):153-61. PubMed ID: 15823501
[TBL] [Abstract][Full Text] [Related]
3. Tumour necrosis factor antagonists improve disease activity but not arterial stiffness in rheumatoid arthritis.
Van Doornum S; McColl G; Wicks IP
Rheumatology (Oxford); 2005 Nov; 44(11):1428-32. PubMed ID: 16076882
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness, predictive response factors, and safety of anti-tumor necrosis factor (TNF) therapies in anti-TNF-naive rheumatoid arthritis.
Fernández-Nebro A; Irigoyen MV; Ureña I; Belmonte-López MA; Coret V; Jiménez-Núñez FG; Díaz-Cordovés G; López-Lasanta MA; Ponce A; Rodríguez-Pérez M; Calero E; González-Santos P
J Rheumatol; 2007 Dec; 34(12):2334-42. PubMed ID: 17985409
[TBL] [Abstract][Full Text] [Related]
5. Anti-tumour necrosis factor-alpha therapy in heart failure: future directions.
Balakumar P; Singh M
Basic Clin Pharmacol Toxicol; 2006 Dec; 99(6):391-7. PubMed ID: 17169118
[TBL] [Abstract][Full Text] [Related]
6. Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis?
Listing J; Strangfeld A; Kekow J; Schneider M; Kapelle A; Wassenberg S; Zink A
Arthritis Rheum; 2008 Mar; 58(3):667-77. PubMed ID: 18311816
[TBL] [Abstract][Full Text] [Related]
7. Differentiating the efficacy of tumor necrosis factor inhibitors.
Haraoui B
J Rheumatol Suppl; 2005 Mar; 74():3-7. PubMed ID: 15742457
[TBL] [Abstract][Full Text] [Related]
8. Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy.
Wolfe F; Michaud K
Am J Med; 2004 Mar; 116(5):305-11. PubMed ID: 14984815
[TBL] [Abstract][Full Text] [Related]
9. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Hyrich KL; Watson KD; Silman AJ; Symmons DP;
Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of rheumatoid arthritis by inhibition of tumor necrosis factor with infliximab or etanercept].
Tijhuis GJ; van de Putte LB; Breedveld FC
Ned Tijdschr Geneeskd; 2001 Sep; 145(39):1880-5. PubMed ID: 11605312
[TBL] [Abstract][Full Text] [Related]
11. TNF-alpha neutralization in cytokine-driven diseases: a mathematical model to account for therapeutic success in rheumatoid arthritis but therapeutic failure in systemic inflammatory response syndrome.
Jit M; Henderson B; Stevens M; Seymour RM
Rheumatology (Oxford); 2005 Mar; 44(3):323-31. PubMed ID: 15585509
[TBL] [Abstract][Full Text] [Related]
12. Anti-TNFalpha therapy of rheumatoid arthritis: what can we learn about chronic disease?
Feldmann M; Brennan FM; Paleolog E; Cope A; Taylor P; Williams R; Woody J; Maini RN
Novartis Found Symp; 2004; 256():53-69; discussion 69-73, 106-11, 266-9. PubMed ID: 15027483
[TBL] [Abstract][Full Text] [Related]
13. [Correlation between different clinical activity and anti CC-P (anti-cyclic citrullinated peptide antibodies) titres in rheumatoid arthritis treated with three different tumor necrosis factors TNF-alpha blockers].
Benucci M; Turchini S; Parrochi P; Boccaccini P; Manetti R; Cammelli E; Manfredi M
Recenti Prog Med; 2006 Mar; 97(3):134-9. PubMed ID: 16700418
[TBL] [Abstract][Full Text] [Related]
14. Anti-tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis.
Catrina AI; af Klint E; Ernestam S; Catrina SB; Makrygiannakis D; Botusan IR; Klareskog L; Ulfgren AK
Arthritis Rheum; 2006 Jan; 54(1):76-81. PubMed ID: 16385498
[TBL] [Abstract][Full Text] [Related]
15. [Treatment of psoriatic arthritis with TNF alpha-antagonists].
Antoni C; Manger B
Z Rheumatol; 2003 Jun; 62(3):235-9. PubMed ID: 12827399
[TBL] [Abstract][Full Text] [Related]
16. [Tumour necrosis factor antagonists: infliximab, adalimumab and etanercept].
Breedveld FC
Ned Tijdschr Geneeskd; 2005 Oct; 149(41):2273-7. PubMed ID: 16240851
[TBL] [Abstract][Full Text] [Related]
17. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A
Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
[TBL] [Abstract][Full Text] [Related]
18. TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice.
Marchesoni A; Zaccara E; Gorla R; Bazzani C; Sarzi-Puttini P; Atzeni F; Caporali R; Bobbio-Pallavicini F; Favalli EG
Ann N Y Acad Sci; 2009 Sep; 1173():837-46. PubMed ID: 19758236
[TBL] [Abstract][Full Text] [Related]
19. Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies.
Jonsdottir T; Forslid J; van Vollenhoven A; Harju A; Brannemark S; Klareskog L; van Vollenhoven RF
Ann Rheum Dis; 2004 Sep; 63(9):1075-8. PubMed ID: 15066863
[TBL] [Abstract][Full Text] [Related]
20. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents.
Finckh A; Ciurea A; Brulhart L; Kyburz D; Möller B; Dehler S; Revaz S; Dudler J; Gabay C;
Arthritis Rheum; 2007 May; 56(5):1417-23. PubMed ID: 17469098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]